{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:01:08Z","timestamp":1780977668006,"version":"3.54.1"},"reference-count":256,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.msard.2026.107247","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:35:11Z","timestamp":1778762111000},"page":"107247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Fluid biomarkers in multiple sclerosis: Indicators of disease activity, progression, and treatment response"],"prefix":"10.1016","volume":"111","author":[{"given":"Farzin","family":"Tahmasbi Arashlow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehra","family":"Fekri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakiba","family":"Salarvandian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiana","family":"Darfarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadijeh","family":"Esmaeilpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0991-7752","authenticated-orcid":false,"given":"Rasoul","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0002","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-33158-8","article-title":"Serum GFAP as a biomarker for disease severity in multiple sclerosis","volume":"8","author":"Abdelhak","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2026.107247_bib0003","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3389\/fneur.2019.00280","article-title":"Glial activation markers in CSF and serum from patients with primary progressive multiple sclerosis: potential of serum GFAP as disease severity marker?","volume":"10","author":"Abdelhak","year":"2019","journal-title":"Front. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2026.107247_bib0004","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jamaneurol.2023.3997","article-title":"Neurofilament light chain elevation and disability progression in multiple sclerosis","volume":"80","author":"Abdelhak","year":"2023","journal-title":"JAMA Neurol."},{"issue":"9","key":"10.1016\/j.msard.2026.107247_bib0005","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S1474-4422(23)00210-7","article-title":"Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study","volume":"22","author":"Abdelhak","year":"2023","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.107247_bib0006","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/acn3.51969","article-title":"Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis","volume":"11","author":"Abdelhak","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.107247_bib0007","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1385\/JMN:18:3:223","article-title":"Dynamic processing of neuropeptides: sequential conformation shaping of neurohypophysial preprohormones during intraneuronal secretory transport","volume":"18","author":"Acher","year":"2002","journal-title":"J. Mol. Neurosci."},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190252","article-title":"Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: a systematic review and meta-analysis","volume":"13","author":"Agah","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.msard.2026.107247_bib0010","doi-asserted-by":"crossref","first-page":"e555","DOI":"10.1212\/NXI.0000000000000555","article-title":"Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS","volume":"6","author":"Akg\u00fcn","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0009","doi-asserted-by":"crossref","first-page":"6903","DOI":"10.1038\/s41467-023-42682-9","article-title":"Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis","volume":"14","author":"\u00c5kesson","year":"2023","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.msard.2026.107247_bib0011","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2013.01.004","article-title":"GDNF, NGF and BDNF as therapeutic options for neurodegeneration","volume":"138","author":"Allen","year":"2013","journal-title":"Pharmacol. Ther."},{"issue":"1\u20132","key":"10.1016\/j.msard.2026.107247_bib0012","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jneuroim.2008.04.025","article-title":"Lymphoid chemokines in chronic neuroinflammation","volume":"198","author":"Aloisi","year":"2008","journal-title":"J. Neuroimmunol."},{"issue":"9","key":"10.1016\/j.msard.2026.107247_bib0013","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1177\/1352458512473362","article-title":"CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions","volume":"19","author":"Alvarez","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107247_bib0014","article-title":"Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures","volume":"1","author":"Alvarez","year":"2015","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"10","key":"10.1016\/j.msard.2026.107247_bib0015","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1001\/archneur.58.10.1602","article-title":"Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years","volume":"58","author":"Amato","year":"2001","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2026.107247_bib0016","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.expneurol.2016.03.012","article-title":"The multiple sclerosis drug fingolimod (FTY720) stimulates neuronal gene expression, axonal growth and regeneration","volume":"279","author":"Anastasiadou","year":"2016","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0017","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12974-019-1517-1","article-title":"Impact of B cells to the pathophysiology of multiple sclerosis","volume":"16","author":"Arneth","year":"2019","journal-title":"J. Neuroinflamm."},{"issue":"11","key":"10.1016\/j.msard.2026.107247_bib0018","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1212\/WNL.0000000000003085","article-title":"Neurofilament light chain level is a weak risk factor for the development of MS","volume":"87","author":"Arrambide","year":"2016","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2026.107247_bib0019","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s00415-010-5863-2","article-title":"Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis","volume":"258","author":"Axelsson","year":"2011","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0020","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1352458513490544","article-title":"Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis","volume":"20","author":"Axelsson","year":"2014","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0021","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-67934-2","article-title":"Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity","volume":"10","author":"Ayrignac","year":"2020","journal-title":"Sci. Rep."},{"issue":"1\u20132","key":"10.1016\/j.msard.2026.107247_bib0022","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jneuroim.2005.07.001","article-title":"Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate","volume":"167","author":"Azoulay","year":"2005","journal-title":"J. Neuroimmunol."},{"issue":"1\u20132","key":"10.1016\/j.msard.2026.107247_bib0023","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jneuroim.2008.01.010","article-title":"Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotection","volume":"195","author":"Azoulay","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2026.107247_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105263","article-title":"Astrocyte activation precedes disease onset in experimental autoimmune encephalomyelitis","volume":"80","author":"Bakirtzis","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"8","key":"10.1016\/j.msard.2026.107247_bib0025","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1517\/14728222.2014.925447","article-title":"Osteopontin as a therapeutic target for cancer","volume":"18","author":"Bandopadhyay","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.msard.2026.107247_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104662","article-title":"Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials","volume":"93","author":"Bar-Or","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.msard.2026.107247_bib0026","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jneuroim.2015.03.011","article-title":"Association of copeptin and cortisol in newly diagnosed multiple sclerosis patients","volume":"282","author":"Baranowska-Bik","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2026.107247_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000200052","article-title":"Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis","volume":"10","author":"Barro","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.msard.2026.107247_bib0029","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/13524585221137697","article-title":"Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients","volume":"29","author":"Barro","year":"2023","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2026.107247_bib0030","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2026.107247_bib0031","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000271","article-title":"Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS","volume":"3","author":"Bergman","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.msard.2026.107247_bib0032","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1001\/jamaneurol.2013.5486","article-title":"Disease activity free status: a new end point for a new era in multiple sclerosis clinical research?","volume":"71","author":"Bevan","year":"2014","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.107247_bib0001","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0033","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1352458520905033","article-title":"Leptin levels are associated with multiple sclerosis risk","volume":"27","author":"Bistr\u00f6m","year":"2021","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2026.107247_bib0034","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/jnr.24224","article-title":"Animal models of multiple sclerosis: focus on experimental autoimmune encephalomyelitis","volume":"96","author":"Bjelobaba","year":"2018","journal-title":"J. Neurosci. Res."},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajmg.b.30154","article-title":"Genetic variation in the brain derived neurotrophic factor gene in Alzheimer's disease","volume":"134b","author":"Bodner","year":"2005","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"10.1016\/j.msard.2026.107247_bib0036","doi-asserted-by":"crossref","DOI":"10.1038\/srep20812","article-title":"Analyzing the release of copeptin from the heart in acute myocardial infarction using a transcoronary gradient model","volume":"6","author":"Boeckel","year":"2016","journal-title":"Sci. Rep."},{"issue":"11\u201312","key":"10.1016\/j.msard.2026.107247_bib0037","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1177\/13524585231198751","article-title":"Accuracy of serum neurofilament light to identify contrast-enhancing lesions in multiple sclerosis","volume":"29","author":"Bose","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107247_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104695","article-title":"Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes","volume":"74","author":"Bose","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107247_bib0039","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1212\/NXI.0000000000200167","article-title":"Increasing neurofilament and glial fibrillary acidic protein after treatment discontinuation predicts multiple sclerosis disease activity","volume":"10","author":"Bose","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"8","key":"10.1016\/j.msard.2026.107247_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011986","article-title":"The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS)","volume":"5","author":"Brettschneider","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2026.107247_bib0041","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jneuroim.2016.01.013","article-title":"YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis","volume":"292","author":"Burman","year":"2016","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.msard.2026.107247_bib0042","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-3083.2005.01649.x","article-title":"Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis","volume":"62","author":"Caggiula","year":"2005","journal-title":"Scand. J. Immunol."},{"issue":"3","key":"10.1016\/j.msard.2026.107247_bib0043","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrn3900","article-title":"Exploring the origins of grey matter damage in multiple sclerosis","volume":"16","author":"Calabrese","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"issue":"Pt 4","key":"10.1016\/j.msard.2026.107247_bib0044","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1093\/brain\/awv017","article-title":"Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes","volume":"138","author":"Cant\u00f3","year":"2015","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.msard.2026.107247_bib0045","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jamaneurol.2019.2137","article-title":"Association between serum neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12 years","volume":"76","author":"Cant\u00f3","year":"2019","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.msard.2026.107247_bib0046","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4103\/1673-5374.300328","article-title":"The Yin-yang of osteopontin in nervous system diseases: damage versus repair","volume":"16","author":"Cappellano","year":"2021","journal-title":"Neural. Regen. Res."},{"issue":"3","key":"10.1016\/j.msard.2026.107247_bib0047","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.cyto.2012.06.017","article-title":"Regulating the immune system via IL-15 transpresentation","volume":"59","author":"Castillo","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.msard.2026.107247_bib0048","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.647618","article-title":"Serum neurofilament light and GFAP are associated with disease severity in inflammatory disorders with aquaporin-4 or myelin oligodendrocyte glycoprotein antibodies","volume":"12","author":"Chang","year":"2021","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.msard.2026.107247_bib0049","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/acn3.638","article-title":"Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis","volume":"5","author":"Chitnis","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2026.107247_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109688","article-title":"Clinical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis","volume":"253","author":"Chitnis","year":"2023","journal-title":"Clin. Immunol."},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0051","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1038\/s41467-024-48602-9","article-title":"Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect clinical and radiographic disease activity in multiple sclerosis","volume":"15","author":"Chitnis","year":"2024","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.msard.2026.107247_bib0052","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1474-4422(25)00249-2","article-title":"Blood and CSF biomarkers for multiple sclerosis: emerging clinical applications","volume":"24","author":"Chitnis","year":"2025","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.107247_bib0053","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/jcb.21911","article-title":"Leptin signaling in breast cancer: an overview","volume":"105","author":"Cirillo","year":"2008","journal-title":"J. Cell Biochem."},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0057","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1474-4422(13)70233-3","article-title":"Body fluid biomarkers in multiple sclerosis","volume":"13","author":"Comabella","year":"2014","journal-title":"Lancet Neurol."},{"issue":"Pt 4","key":"10.1016\/j.msard.2026.107247_bib0054","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/brain\/awq035","article-title":"Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis","volume":"133","author":"Comabella","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.msard.2026.107247_bib0055","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1212\/NXI.0000000000001082","article-title":"CSF chitinase 3-like 2 is associated with long-term disability progression in patients with progressive multiple sclerosis","volume":"8","author":"Comabella","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0056","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/13524585211010082","article-title":"CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event","volume":"28","author":"Comabella","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107247_bib0058","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/212893","article-title":"The impact of osteopontin gene variations on multiple sclerosis development and progression","volume":"2012","author":"Comi","year":"2012","journal-title":"Clin. Dev. Immunol."},{"issue":"Pt 3","key":"10.1016\/j.msard.2026.107247_bib0059","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/brain\/awl007","article-title":"Natural history of multiple sclerosis: a unifying concept","volume":"129","author":"Confavreux","year":"2006","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.msard.2026.107247_bib0060","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/1756285612461165","article-title":"Rituximab combination therapy in relapsing multiple sclerosis","volume":"5","author":"Cross","year":"2012","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2026.107247_bib0061","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.brainres.2007.04.070","article-title":"Strain rate-dependent induction of reactive astrogliosis and cell death in three-dimensional neuronal-astrocytic co-cultures","volume":"1158","author":"Cullen","year":"2007","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0062","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1352458515604383","article-title":"No evidence of disease activity in multiple sclerosis: implications on cognition and brain atrophy","volume":"22","author":"Damasceno","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107247_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101409","article-title":"Leptin rs7799039 polymorphism is associated with multiple sclerosis risk in Kuwait","volume":"36","author":"Dashti","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107247_bib0064","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.msard.2019.07.030","article-title":"The predictive value of CSF multiple assay in multiple sclerosis: a single center experience","volume":"35","author":"De Fino","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2026.107247_bib0065","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40263-014-0140-z","article-title":"Clinical relevance of brain volume measures in multiple sclerosis","volume":"28","author":"De Stefano","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2026.107247_bib0066","article-title":"Fluid biomarkers in multiple sclerosis: from current to future applications","volume":"44","author":"Di Filippo","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"issue":"4","key":"10.1016\/j.msard.2026.107247_bib0067","article-title":"Intrathecally produced CXCL13: a predictive biomarker in multiple sclerosis","volume":"6","author":"DiSano","year":"2020","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"6","key":"10.1016\/j.msard.2026.107247_bib0068","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.107247_bib0069","doi-asserted-by":"crossref","first-page":"172","DOI":"10.11613\/BM.2013.021","article-title":"Copeptin and its potential role in diagnosis and prognosis of various diseases","volume":"23","author":"Dobsa","year":"2013","journal-title":"Biochem. Med. (Zagreb)"},{"issue":"Suppl 6","key":"10.1016\/j.msard.2026.107247_bib0070","doi-asserted-by":"crossref","first-page":"s53","DOI":"10.7861\/clinmedicine.16-6-s53","article-title":"Multiple sclerosis, a treatable disease","volume":"16","author":"Doshi","year":"2016","journal-title":"Clin. Med. (Lond.)"},{"key":"10.1016\/j.msard.2026.107247_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2025.112992","article-title":"Blood neurofilament light chain in patients with multiple sclerosis: a systematic review and updated meta-analysis","volume":"213","author":"Ebrahimi","year":"2026","journal-title":"Exp. Gerontol."},{"issue":"2","key":"10.1016\/j.msard.2026.107247_bib0072","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0092-8674(03)00035-7","article-title":"The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function","volume":"112","author":"Egan","year":"2003","journal-title":"Cell"},{"issue":"9\u201310","key":"10.1016\/j.msard.2026.107247_bib0073","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1023\/A:1007677003387","article-title":"Glial fibrillary acidic protein: gFAP-thirty-one years (1969-2000)","volume":"25","author":"Eng","year":"2000","journal-title":"Neurochem Res."},{"issue":"3","key":"10.1016\/j.msard.2026.107247_bib0074","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1191\/1352458502ms797oa","article-title":"Cortisol is increased in postmortem cerebrospinal fluid of multiple sclerosis patients: relationship with cytokines and sepsis","volume":"8","author":"Erkut","year":"2002","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2026.107247_bib0086","doi-asserted-by":"crossref","first-page":"7676","DOI":"10.3390\/ijms13067676","article-title":"Proteomic analysis of cerebrospinal fluid in a fulminant case of multiple sclerosis","volume":"13","author":"F\u00fcvesi","year":"2012","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.msard.2026.107247_bib0075","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1471-4159.2010.06982.x","article-title":"Are current disease-modifying therapeutics in multiple sclerosis justified on the basis of studies in experimental autoimmune encephalomyelitis?","volume":"115","author":"Farooqi","year":"2010","journal-title":"J. Neurochem."},{"issue":"18","key":"10.1016\/j.msard.2026.107247_bib0076","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241814192","article-title":"Antibody content against Epstein-Barr Virus in blood extracellular vesicles correlates with disease activity and brain volume in patients with relapsing-remitting multiple sclerosis","volume":"24","author":"Fern\u00e1ndez-Fournier","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2026.107247_bib0077","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jneuroim.2015.04.011","article-title":"Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: association with oligoclonal IgM bands and prediction of Multiple Sclerosis diagnosis","volume":"283","author":"Ferraro","year":"2015","journal-title":"J. Neuroimmunol."},{"issue":"4","key":"10.1016\/j.msard.2026.107247_bib0078","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S1474-4422(12)70003-0","article-title":"Association between pathological and MRI findings in multiple sclerosis","volume":"11","author":"Filippi","year":"2012","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.107247_bib0079","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1474-4422(15)00393-2","article-title":"MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines","volume":"15","author":"Filippi","year":"2016","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.msard.2026.107247_bib0080","article-title":"Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis","volume":"2013","author":"Filippini","year":"2013","journal-title":"Cochr. Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.msard.2026.107247_bib0081","article-title":"Rituximab for people with multiple sclerosis","volume":"3","author":"Filippini","year":"2025","journal-title":"Cochr. Database Syst. Rev."},{"issue":"9","key":"10.1016\/j.msard.2026.107247_bib0082","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209357","article-title":"Temporal relationship between serum neurofilament light chain and radiologic disease activity in patients with multiple sclerosis","volume":"102","author":"Fox","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107247_bib0083","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102534","article-title":"The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years","volume":"46","author":"Friedova","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2026.107247_bib0084","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrneurol.2014.37","article-title":"Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis","volume":"10","author":"Friese","year":"2014","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0085","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ajmg.b.30986","article-title":"Sexually dimorphic effect of the Val66Met polymorphism of BDNF on susceptibility to Alzheimer's disease: new data and meta-analysis","volume":"153b","author":"Fukumoto","year":"2010","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"issue":"Pt 1","key":"10.1016\/j.msard.2026.107247_bib0087","first-page":"36","article-title":"BDNF splice variants from the second promoter cluster support cell survival of differentiated neuroblastoma upon cytotoxic stress","volume":"122","author":"Gabriele","year":"2009","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.msard.2026.107247_bib0088","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103922","article-title":"Biomarker panel increases accuracy for identification of an MS relapse beyond sNfL","volume":"63","author":"Gawde","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.msard.2026.107247_bib0089","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/S1474-4422(12)70230-2","article-title":"Measurement and clinical effect of grey matter pathology in multiple sclerosis","volume":"11","author":"Geurts","year":"2012","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.107247_bib0090","article-title":"Transforming multiple sclerosis management through artificial intelligence: a comprehensive narrative review of clinical, imaging, digital, and molecular applications","volume":"47","author":"Ghaffary","year":"2025","journal-title":"Appl. Med. Inform."},{"issue":"3","key":"10.1016\/j.msard.2026.107247_bib0091","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11011-020-00648-6","article-title":"A comprehensive review on the role of chemokines in the pathogenesis of multiple sclerosis","volume":"36","author":"Ghafouri-Fard","year":"2021","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.msard.2026.107247_bib0092","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3389\/fneur.2019.01008","article-title":"Combined cerebrospinal fluid neurofilament light chain protein and chitinase-3 like-1 levels in defining disease course and prognosis in multiple sclerosis","volume":"10","author":"Gil-Perotin","year":"2019","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.107247_bib0093","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1177\/1352458513494490","article-title":"Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis","volume":"20","author":"Giorgio","year":"2014","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2026.107247_bib0094","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.msard.2015.04.006","article-title":"Is it time to target no evident disease activity (NEDA) in multiple sclerosis?","volume":"4","author":"Giovannoni","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1\u20132","key":"10.1016\/j.msard.2026.107247_bib0096","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jneuroim.2005.04.014","article-title":"Hypothalamo-pituitary-adrenal axis activity predicts disease progression in multiple sclerosis","volume":"165","author":"Gold","year":"2005","journal-title":"J. Neuroimmunol."},{"issue":"8","key":"10.1016\/j.msard.2026.107247_bib0095","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/brain\/awl075","article-title":"Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research","volume":"129","author":"Gold","year":"2006","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0097","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/ana.22247","article-title":"Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab","volume":"69","author":"Gunnarsson","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2026.107247_bib0101","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1196\/annals.1351.044","article-title":"Leptin is a link between adipose tissue and inflammation","volume":"1069","author":"H\u00e4rle","year":"2006","journal-title":"Ann. N.Y. Acad. Sci."},{"issue":"2","key":"10.1016\/j.msard.2026.107247_bib0104","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/1352458518819380","article-title":"Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity","volume":"26","author":"H\u00f6gel","year":"2020","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2026.107247_bib0098","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1034\/j.1600-0404.2003.00197.x","article-title":"Cerebrospinal fluid markers in MS patients and their healthy siblings","volume":"109","author":"Haghighi","year":"2004","journal-title":"Acta Neurol. Scand."},{"issue":"34","key":"10.1016\/j.msard.2026.107247_bib0099","doi-asserted-by":"crossref","first-page":"25803","DOI":"10.1016\/S0021-9258(19)74461-5","article-title":"Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family","volume":"268","author":"Hakala","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0100","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s10875-013-9965-3","article-title":"Increased circulating Th17 cell populations and elevated CSF osteopontin and IL-17 concentrations in patients with Guillain-Barr\u00e9 syndrome","volume":"34","author":"Han","year":"2014","journal-title":"J. Clin. Immunol."},{"issue":"3","key":"10.1016\/j.msard.2026.107247_bib0102","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1474-4422(09)70021-3","article-title":"Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab safety and efficacy in relapsing-remitting multiple sclerosis (AFFIRM) study","volume":"8","author":"Havrdova","year":"2009","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2026.107247_bib0103","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00401-023-02627-4","article-title":"Myeloid cell iron uptake pathways and paramagnetic rim formation in multiple sclerosis","volume":"146","author":"Hofmann","year":"2023","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.msard.2026.107247_bib0105","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fnmol.2020.00038","article-title":"CNS-derived blood exosomes as a promising source of biomarkers: opportunities and challenges","volume":"13","author":"Hornung","year":"2020","journal-title":"Front. Mol. Neurosci."},{"issue":"4","key":"10.1016\/j.msard.2026.107247_bib0106","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11910-018-0827-5","article-title":"Insights into the mechanisms that may clarify obesity as a risk factor for multiple sclerosis","volume":"18","author":"Huitema","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0107","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ana.10766","article-title":"Impaired hypothalamus-pituitary-adrenal axis activity and more severe multiple sclerosis with hypothalamic lesions","volume":"55","author":"Huitinga","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2026.107247_bib0108","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.738442","article-title":"The emerging role of neural cell-derived exosomes in intercellular communication in health and neurodegenerative diseases","volume":"15","author":"Huo","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.msard.2026.107247_bib0110","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3389\/fneur.2020.00608","article-title":"A score based on NfL and glial markers may differentiate between relapsing\u2013remitting and progressive MS course","volume":"11","author":"Huss","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2026.107247_bib0109","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3389\/fneur.2020.00608","article-title":"A score based on NfL and glial markers may differentiate between relapsing-remitting and progressive MS course","volume":"11","author":"Huss","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2026.107247_bib0111","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.bbi.2013.08.009","article-title":"The improvement of cognitive functions is associated with a decrease of plasma osteopontin levels in Natalizumab treated relapsing multiple sclerosis","volume":"35","author":"Iaffaldano","year":"2014","journal-title":"Brain Behav. Immun."},{"issue":"2","key":"10.1016\/j.msard.2026.107247_bib0112","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/cei.12878","article-title":"Circulating immune cells in multiple sclerosis","volume":"187","author":"Jones","year":"2017","journal-title":"Clin. Exp. Immunol."},{"issue":"Pt 11","key":"10.1016\/j.msard.2026.107247_bib0113","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1093\/brain\/awv258","article-title":"Defining reliable disability outcomes in multiple sclerosis","volume":"138","author":"Kalincik","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.msard.2026.107247_bib0115","article-title":"The stress hormone copeptin: a new prognostic biomarker in acute illness","volume":"140","author":"Katan","year":"2010","journal-title":"Swiss Med. Wkly."},{"issue":"2","key":"10.1016\/j.msard.2026.107247_bib0116","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/cc6799","article-title":"Copeptin: a new and promising diagnostic and prognostic marker","volume":"12","author":"Katan","year":"2008","journal-title":"Crit. Care"},{"issue":"6","key":"10.1016\/j.msard.2026.107247_bib0114","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/ana.21783","article-title":"Copeptin: a novel, independent prognostic marker in patients with ischemic stroke","volume":"66","author":"Katan","year":"2009","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.107247_bib0117","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060647","article-title":"Cortisol awakening response is linked to disease course and progression in multiple sclerosis","volume":"8","author":"Kern","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.msard.2026.107247_bib0118","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/1352458510389102","article-title":"Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course","volume":"17","author":"Khademi","year":"2011","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2026.107247_bib0119","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/ana.22438","article-title":"The neurofilament light chain is not stable in vitro","volume":"69","author":"Koel-Simmelink","year":"2011","journal-title":"Ann. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.msard.2026.107247_bib0120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jim.2013.11.008","article-title":"The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA","volume":"402","author":"Koel-Simmelink","year":"2014","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.msard.2026.107247_bib0121","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1749-6632.2001.tb03936.x","article-title":"The prothrombotic effects of leptin possible implications for the risk of cardiovascular disease in obesity","volume":"947","author":"Konstantinides","year":"2001","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.msard.2026.107247_bib0122","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1172\/jci.insight.161415","article-title":"Enhancing the clinical value of serum neurofilament light chain measurement","volume":"7","author":"Kosa","year":"2022","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0123","doi-asserted-by":"crossref","first-page":"7670","DOI":"10.1038\/s41467-022-35357-4","article-title":"Molecular models of multiple sclerosis severity identify heterogeneity of pathogenic mechanisms","volume":"13","author":"Kosa","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.msard.2026.107247_bib0124","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jocn.2020.04.095","article-title":"Plasma copeptin levels in patients with multiple sclerosis","volume":"78","author":"Koseoglu","year":"2020","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.msard.2026.107247_bib0125","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1742-2094-9-93","article-title":"CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation","volume":"9","author":"Kowarik","year":"2012","journal-title":"J. Neuroinflamm."},{"issue":"9 Suppl","key":"10.1016\/j.msard.2026.107247_bib0126","doi-asserted-by":"crossref","first-page":"S432","DOI":"10.1097\/01.CCM.0000134267.91520.C0","article-title":"Vasopressin during cardiopulmonary resuscitation: a progress report","volume":"32","author":"Krismer","year":"2004","journal-title":"Crit. Care Med."},{"issue":"7","key":"10.1016\/j.msard.2026.107247_bib0127","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.bbapap.2014.12.013","article-title":"Cerebrospinal fluid proteomics in multiple sclerosis","volume":"1854","author":"Kroksveen","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"issue":"Pt 1","key":"10.1016\/j.msard.2026.107247_bib0128","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/brain\/awh680","article-title":"Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment","volume":"129","author":"Krumbholz","year":"2006","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.msard.2026.107247_bib0129","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1177\/1352458514568827","article-title":"Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study","volume":"21","author":"Kuhle","year":"2015","journal-title":"Mult. Scler."},{"issue":"16","key":"10.1016\/j.msard.2026.107247_bib0130","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1212\/WNL.0000000000001491","article-title":"Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis","volume":"84","author":"Kuhle","year":"2015","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2026.107247_bib0131","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1212\/WNL.0000000000003653","article-title":"Serum neurofilament is associated with progression of brain atrophy and disability in early MS","volume":"88","author":"Kuhle","year":"2017","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.msard.2026.107247_bib0132","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2026.107247_bib0133","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nri1350","article-title":"The weight of leptin in immunity","volume":"4","author":"La Cava","year":"2004","journal-title":"Nat. Rev. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.msard.2026.107247_bib0134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2013.05.010","article-title":"Pathology and disease mechanisms in different stages of multiple sclerosis","volume":"333","author":"Lassmann","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2026.107247_bib0136","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1146\/annurev.ne.19.030196.001155","article-title":"Neuronal intermediate filaments","volume":"19","author":"Lee","year":"1996","journal-title":"Annu. Rev. Neurosci."},{"issue":"6","key":"10.1016\/j.msard.2026.107247_bib0135","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1083\/jcb.122.6.1337","article-title":"Neurofilaments are obligate heteropolymers in vivo","volume":"122","author":"Lee","year":"1993","journal-title":"J. Cell Biol."},{"issue":"4","key":"10.1016\/j.msard.2026.107247_bib0137","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1084\/jem.187.4.655","article-title":"B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1\/CXCR5","volume":"187","author":"Legler","year":"1998","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0138","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12974-019-1601-6","article-title":"Cytokine and immune cell profiling in the cerebrospinal fluid of patients with neuro-inflammatory diseases","volume":"16","author":"Lepennetier","year":"2019","journal-title":"J. Neuroinflamm."},{"issue":"16","key":"10.1016\/j.msard.2026.107247_bib0139","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1093\/emboj\/16.16.4999","article-title":"NMR structure of the death domain of the p75 neurotrophin receptor","volume":"16","author":"Liepinsh","year":"1997","journal-title":"Embo J."},{"issue":"7","key":"10.1016\/j.msard.2026.107247_bib0140","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1177\/1352458512463482","article-title":"Multiple sclerosis risk genotypes correlate with an elevated cerebrospinal fluid level of the suggested prognostic marker CXCL13","volume":"19","author":"Lind\u00e9n","year":"2013","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0141","article-title":"Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS","volume":"8","author":"Lokhande","year":"2022","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2026.107247_bib0142","doi-asserted-by":"crossref","first-page":"514","DOI":"10.12688\/f1000research.14556.2","article-title":"Role of CXCL13 in the formation of the meningeal tertiary lymphoid organ in multiple sclerosis","volume":"7","author":"Londo\u00f1o","year":"2018","journal-title":"F1000Res"},{"issue":"3","key":"10.1016\/j.msard.2026.107247_bib0144","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"24","key":"10.1016\/j.msard.2026.107247_bib0145","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1212\/WNL.0000000000009636","article-title":"The 2013 clinical course descriptors for multiple sclerosis: a clarification","volume":"94","author":"Lublin","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0143","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.msard.2011.08.001","article-title":"Disease activity free status in MS","volume":"1","author":"Lublin","year":"2012","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"15","key":"10.1016\/j.msard.2026.107247_bib0146","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkr424","article-title":"Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood","volume":"39","author":"Lundberg","year":"2011","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.msard.2026.107247_bib0147","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/jnnp.64.3.402","article-title":"Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis","volume":"64","author":"Lycke","year":"1998","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9","key":"10.1016\/j.msard.2026.107247_bib0148","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S1474-4422(03)00504-0","article-title":"Spinal-cord MRI in multiple sclerosis","volume":"2","author":"Lycklama","year":"2003","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2026.107247_bib0165","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/ene.12960","article-title":"Cerebrospinal fluid chitinase-3-like 2 and chitotriosidase are potential prognostic biomarkers in early multiple sclerosis","volume":"23","author":"M\u00f8llgaard","year":"2016","journal-title":"Eur. J. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2026.107247_bib0149","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/acn3.52187","article-title":"Serum glial fibrillary acidic protein predicts disease progression in multiple sclerosis","volume":"11","author":"Madill","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"Pt 4","key":"10.1016\/j.msard.2026.107247_bib0150","first-page":"1089","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology","volume":"130","author":"Magliozzi","year":"2007","journal-title":"Brain"},{"issue":"4949 Pt 1","key":"10.1016\/j.msard.2026.107247_bib0151","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1126\/science.247.4949.1446","article-title":"Neurotrophin-3: a neurotrophic factor related to NGF and BDNF","volume":"247","author":"Maisonpierre","year":"1990","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.msard.2026.107247_bib0152","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/0888-7543(91)90436-I","article-title":"Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations","volume":"10","author":"Maisonpierre","year":"1991","journal-title":"Genomics"},{"issue":"12","key":"10.1016\/j.msard.2026.107247_bib0153","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1212\/01.WNL.0000098880.19793.B6","article-title":"Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS","volume":"61","author":"Malmestr\u00f6m","year":"2003","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2026.107247_bib0154","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/acn3.51291","article-title":"Obesity and the risk of Multiple sclerosis. The role of leptin","volume":"8","author":"Marrodan","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2026.107247_bib0155","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1177\/1352458514549397","article-title":"Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis","volume":"21","author":"Mart\u00ednez","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107247_bib0156","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jneuroim.2016.12.006","article-title":"Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis","volume":"303","author":"Matute-Blanch","year":"2017","journal-title":"J. Neuroimmunol."},{"issue":"8","key":"10.1016\/j.msard.2026.107247_bib0157","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.msard.2026.107247_bib0158","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","article-title":"Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis","volume":"80","author":"Meier","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2026.107247_bib0159","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/1471-2377-13-172","article-title":"Increased leptin and A-FABP levels in relapsing and progressive forms of MS","volume":"13","author":"Messina","year":"2013","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2026.107247_bib0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2026.107037","article-title":"Associations between personality traits and cognitive function in multiple sclerosis and neuromyelitis optica spectrum disorder: a cross-sectional study","volume":"108","author":"Mirmosayyeb","year":"2026","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1\u20132","key":"10.1016\/j.msard.2026.107247_bib0161","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jneuroim.2007.10.013","article-title":"BDNF A196G and C270T gene polymorphisms and susceptibility to multiple sclerosis in the Polish population. Gender differences","volume":"193","author":"Mirowska-Guzel","year":"2008","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.msard.2026.107247_bib0162","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/1352458513496344","article-title":"Cortical lesion load correlates with diffuse injury of multiple sclerosis normal appearing white matter","volume":"20","author":"Mistry","year":"2014","journal-title":"Mult. Scler."},{"issue":"11","key":"10.1016\/j.msard.2026.107247_bib0163","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1177\/1352458514526083","article-title":"Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes","volume":"20","author":"Mitjana","year":"2014","journal-title":"Mult. Scler."},{"issue":"14","key":"10.1016\/j.msard.2026.107247_bib0164","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1177\/1352458515574148","article-title":"Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis","volume":"21","author":"Modvig","year":"2015","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2026.107247_bib0166","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1515\/revneuro-2020-0145","article-title":"Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis","volume":"32","author":"Momtazmanesh","year":"2021","journal-title":"Rev. Neurosci."},{"issue":"4","key":"10.1016\/j.msard.2026.107247_bib0167","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/jamaneurol.2023.0010","article-title":"Association of serum neurofilament light chain levels at disease onset with disability worsening in patients with a first demyelinating multiple sclerosis event not treated with high-efficacy drugs","volume":"80","author":"Monreal","year":"2023","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.107247_bib0168","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.tem.2007.11.001","article-title":"Copeptin: clinical use of a new biomarker","volume":"19","author":"Morgenthaler","year":"2008","journal-title":"Trends Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.msard.2026.107247_bib0169","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001004","article-title":"Exosomes from subjects with multiple sclerosis express EBV-derived proteins and activate monocyte-derived macrophages","volume":"8","author":"Mrad","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.msard.2026.107247_bib0170","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1177\/1352458519879303","article-title":"microRNA and exosome profiling in multiple sclerosis","volume":"26","author":"Mycko","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107247_bib0175","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/ijms232012361","article-title":"Ella versus Simoa serum neurofilament assessment to monitor treatment response in highly active multiple sclerosis patients","volume":"23","author":"N\u00f6tzel","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.msard.2026.107247_bib0171","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1007\/s00415-023-11841-9","article-title":"Serum levels of neurofilament light chains in pediatric multiple sclerosis: a systematic review and meta-analysis","volume":"270","author":"Niculae","year":"2023","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0173","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0006-8993(03)03219-0","article-title":"Elevated neurofilament levels in neurological diseases","volume":"987","author":"Norgren","year":"2003","journal-title":"Brain Res."},{"issue":"9","key":"10.1016\/j.msard.2026.107247_bib0172","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1212\/01.WNL.0000142988.49341.D1","article-title":"Neurofilament and glial fibrillary acidic protein in multiple sclerosis","volume":"63","author":"Norgren","year":"2004","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2026.107247_bib0174","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1212\/WNL.40.6.971","article-title":"Interrater variability with the expanded disability status scale (EDSS) and functional systems (FS) in a multiple sclerosis clinical trial. The Canadian cooperation MS study group","volume":"40","author":"Noseworthy","year":"1990","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2026.107247_bib0176","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/jnc.13881","article-title":"Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis","volume":"141","author":"Novakova","year":"2017","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0177","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/1352458516639384","article-title":"Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis","volume":"23","author":"Novakova","year":"2017","journal-title":"Mult. Scler."},{"issue":"22","key":"10.1016\/j.msard.2026.107247_bib0178","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","article-title":"Monitoring disease activity in multiple sclerosis using serum neurofilament light protein","volume":"89","author":"Novakova","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107247_bib0179","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102463","article-title":"NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS","volume":"46","author":"Novakova","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107247_bib0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105004","article-title":"A comparison of serum inflammatory parameters in progressive forms of multiple sclerosis","volume":"79","author":"Nowak-Kiczmer","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2026.107247_bib0181","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/ana.25691","article-title":"CHIT1 at diagnosis reflects long-term multiple sclerosis disease activity","volume":"87","author":"Oldoni","year":"2020","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0182","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12974-019-1440-5","article-title":"Cerebrospinal fluid biomarkers for predicting development of multiple sclerosis in acute optic neuritis: a population-based prospective cohort study","volume":"16","author":"Olesen","year":"2019","journal-title":"J. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.msard.2026.107247_bib0183","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.neulet.2005.02.017","article-title":"Risk of late-onset Alzheimer's disease associated with BDNF C270T polymorphism","volume":"381","author":"Olin","year":"2005","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.msard.2026.107247_bib0184","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102923","article-title":"Microstructural and functional brain abnormalities in multiple sclerosis predicted by osteopontin and neurofilament light","volume":"51","author":"Orsi","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107247_bib0186","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1212\/NXI.0000000000000815","article-title":"CSF chitinase 3-like-1 association with disability of primary progressive MS","volume":"7","author":"P\u00e9rez-Miralles","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"Suppl 200","key":"10.1016\/j.msard.2026.107247_bib0185","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ane.12651","article-title":"Evaluation of cognition and fatigue in multiple sclerosis: daily practice and future directions","volume":"134","author":"Penner","year":"2016","journal-title":"Acta Neurol. Scand."},{"issue":"8","key":"10.1016\/j.msard.2026.107247_bib0187","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/mp.2009.24","article-title":"Population genetic study of the brain-derived neurotrophic factor (BDNF) gene","volume":"15","author":"Petryshen","year":"2010","journal-title":"Mol. Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.msard.2026.107247_bib0188","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jns.2005.03.015","article-title":"Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss","volume":"233","author":"Petzold","year":"2005","journal-title":"J. Neurol. Sci."},{"issue":"6","key":"10.1016\/j.msard.2026.107247_bib0189","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1001\/archneurol.2010.99","article-title":"Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis","volume":"67","author":"Piccio","year":"2010","journal-title":"Arch Neurol."},{"issue":"8","key":"10.1016\/j.msard.2026.107247_bib0190","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1177\/1352458517715132","article-title":"Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod","volume":"24","author":"Piehl","year":"2018","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0191","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3325\/cmj.2009.50.43","article-title":"Ethnic differences in brain-derived neurotrophic factor Val66Met polymorphism in Croatian and Korean healthy participants","volume":"50","author":"Pivac","year":"2009","journal-title":"Croat Med. J."},{"issue":"9","key":"10.1016\/j.msard.2026.107247_bib0192","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.msard.2026.107247_bib0193","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"issue":"Suppl 2","key":"10.1016\/j.msard.2026.107247_bib0194","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10072-008-0939-9","article-title":"Clinical markers of therapeutic response to disease modifying drugs","volume":"29","author":"Pozzilli","year":"2008","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2026.107247_bib0195","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jneuroim.2016.11.007","article-title":"Early cognitive impairment along with decreased stress-induced BDNF in male and female patients with newly diagnosed multiple sclerosis","volume":"302","author":"Prokopova","year":"2017","journal-title":"J. Neuroimmunol."},{"issue":"3","key":"10.1016\/j.msard.2026.107247_bib0196","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ygeno.2007.05.004","article-title":"Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters","volume":"90","author":"Pruunsild","year":"2007","journal-title":"Genomics"},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0197","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12974-016-0785-2","article-title":"BAFF Index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset","volume":"14","author":"Puthenparampil","year":"2017","journal-title":"J. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.msard.2026.107247_bib0198","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1468-1331.2008.02519.x","article-title":"Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis","volume":"16","author":"Putzki","year":"2009","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.107247_bib0199","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000276400","article-title":"Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland","volume":"63","author":"Putzki","year":"2010","journal-title":"Eur. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2026.107247_bib0200","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/ene.13687","article-title":"Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain","volume":"25","author":"Quintana","year":"2018","journal-title":"Eur. J. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2026.107247_bib0201","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1177\/1352458511398887","article-title":"Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid","volume":"17","author":"Ragheb","year":"2011","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2026.107247_bib0202","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/archneur.1994.00540140057015","article-title":"Adrenal size is increased in multiple sclerosis","volume":"51","author":"Reder","year":"1994","journal-title":"Arch. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.107247_bib0203","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1006\/geno.1997.4778","article-title":"Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation","volume":"43","author":"Rehli","year":"1997","journal-title":"Genomics"},{"issue":"6","key":"10.1016\/j.msard.2026.107247_bib0204","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nbt.1641","article-title":"Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations","volume":"28","author":"Rissin","year":"2010","journal-title":"Nat. Biotechnol."},{"issue":"12","key":"10.1016\/j.msard.2026.107247_bib0205","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1177\/0022034515605270","article-title":"Osteopontin in immune-mediated diseases","volume":"94","author":"Rittling","year":"2015","journal-title":"J. Dent. Res."},{"key":"10.1016\/j.msard.2026.107247_bib0206","article-title":"Anti-CD20 B cell treatment for relapsing multiple sclerosis","volume":"11","author":"Roach","year":"2020","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0207","first-page":"110","article-title":"Th1\/Th2 cytokine balance and nitric oxide in cerebrospinal fluid and serum from patients with multiple sclerosis","volume":"13","author":"Rodr\u00edguez-S\u00e1inz Mdel","year":"2002","journal-title":"Eur. Cytokine Netw."},{"issue":"7","key":"10.1016\/j.msard.2026.107247_bib0208","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1177\/1352458518774880","article-title":"CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage","volume":"25","author":"Romme Christensen","year":"2019","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2026.107247_bib0209","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1177\/13524585211039104","article-title":"Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study","volume":"28","author":"Rosenstein","year":"2022","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2026.107247_bib0210","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/acn3.51060","article-title":"Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis","volume":"7","author":"Rosso","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.107247_bib0211","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/jon.12826","article-title":"MRI lesion State modulates the relationship between serum neurofilament light and age in multiple sclerosis","volume":"31","author":"Rosso","year":"2021","journal-title":"J. Neuroimaging"},{"issue":"2","key":"10.1016\/j.msard.2026.107247_bib0212","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","article-title":"Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort","volume":"72","author":"Rotstein","year":"2015","journal-title":"JAMA Neurol."},{"issue":"9","key":"10.1016\/j.msard.2026.107247_bib0213","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2026.107247_bib0214","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/1352458509359725","article-title":"Neurofilament light as a prognostic marker in multiple sclerosis","volume":"16","author":"Salzer","year":"2010","journal-title":"Mult. Scler."},{"issue":"1\u20132","key":"10.1016\/j.msard.2026.107247_bib0215","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0165-5728(02)00319-3","article-title":"Brain-derived neurotrophic factor in patients with multiple sclerosis","volume":"132","author":"Sarchielli","year":"2002","journal-title":"J. Neuroimmunol."},{"issue":"Pt 7","key":"10.1016\/j.msard.2026.107247_bib0216","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/brain\/awq118","article-title":"The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability","volume":"133","author":"Scalfari","year":"2010","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.msard.2026.107247_bib0217","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1111\/ene.15865","article-title":"Relevance of dedicated multiple sclerosis serum biomarkers in predicting contrast enhancement with gadolinium: results from the REDUCE-GAD trial","volume":"30","author":"Schaefer","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2026.107247_bib0218","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000906","article-title":"Chitinase 3-like 1 and neurofilament light chain in CSF and CNS atrophy in MS","volume":"8","author":"Schneider","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.msard.2026.107247_bib0219","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/13524585231219131","article-title":"Plasma glial fibrillary acidic protein levels correlate with paramagnetic rim lesions in people with radiologically isolated syndrome","volume":"30","author":"Schneider","year":"2024","journal-title":"Mult. Scler."},{"issue":"23","key":"10.1016\/j.msard.2026.107247_bib0220","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1212\/WNL.0b013e3181c5b457","article-title":"Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS","volume":"73","author":"Sellebjerg","year":"2009","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2026.107247_bib0221","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s004150170229","article-title":"A modified protocol to improve the detection of enhancing brain and spinal cord lesions in multiple sclerosis","volume":"248","author":"Silver","year":"2001","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0222","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/ana.24018","article-title":"Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis","volume":"75","author":"Sormani","year":"2014","journal-title":"Ann. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2026.107247_bib0223","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.it.2005.08.014","article-title":"Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis","volume":"26","author":"Steinman","year":"2005","journal-title":"Trends Immunol."},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0224","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/ana.20913","article-title":"How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis","volume":"60","author":"Steinman","year":"2006","journal-title":"Ann. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2026.107247_bib0225","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/j.peptides.2005.04.019","article-title":"Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients","volume":"26","author":"Struck","year":"2005","journal-title":"Peptides"},{"key":"10.1016\/j.msard.2026.107247_bib0226","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102870","article-title":"A candidate biomarker of glial fibrillary acidic protein in CSF and blood in differentiating multiple sclerosis and its subtypes: a systematic review and meta-analysis","volume":"51","author":"Sun","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1\u20132","key":"10.1016\/j.msard.2026.107247_bib0227","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jns.2013.04.024","article-title":"Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity","volume":"331","author":"Szalardy","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2026.107247_bib0228","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102697","article-title":"CSF levels of HoxB3 and YKL-40 may predict conversion from clinically isolated syndrome to relapsing remitting multiple sclerosis","volume":"48","author":"Tamam","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"22","key":"10.1016\/j.msard.2026.107247_bib0230","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181c47cc2","article-title":"A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking","volume":"73","author":"Teunissen","year":"2009","journal-title":"Neurology"},{"issue":"15","key":"10.1016\/j.msard.2026.107247_bib0231","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1212\/WNL.0b013e3181a0fe3f","article-title":"Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis","volume":"72","author":"Teunissen","year":"2009","journal-title":"Neurology"},{"issue":"13","key":"10.1016\/j.msard.2026.107247_bib0229","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1177\/1352458513488232","article-title":"Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis","volume":"19","author":"Teunissen","year":"2013","journal-title":"Mult. Scler."},{"issue":"10","key":"10.1016\/j.msard.2026.107247_bib0232","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2023.100629","article-title":"Methods to discover and validate biofluid-based biomarkers in neurodegenerative dementias","volume":"22","author":"Teunissen","year":"2023","journal-title":"Mol. Cell Proteom."},{"issue":"10130","key":"10.1016\/j.msard.2026.107247_bib0233","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.msard.2026.107247_bib0234","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.107247_bib0235","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1212\/WNL.46.2.373","article-title":"Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis","volume":"46","author":"Thorpe","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107247_bib0236","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/diagnostics12112571","article-title":"Serum and CSF biomarkers predict active early cognitive decline rather than established cognitive impairment at the moment of RRMS diagnosis","volume":"12","author":"Tiu","year":"2022","journal-title":"Diagnostics"},{"issue":"11","key":"10.1016\/j.msard.2026.107247_bib0237","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1373\/clinchem.2007.091181","article-title":"Ultrasensitive flow-based immunoassays using single-molecule counting","volume":"53","author":"Todd","year":"2007","journal-title":"Clin. Chem."},{"issue":"3","key":"10.1016\/j.msard.2026.107247_bib0238","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3174\/ajnr.A4539","article-title":"Revised recommendations of the consortium of MS centers task force for a standardized MRI protocol and clinical guidelines for the diagnosis and follow-up of multiple sclerosis","volume":"37","author":"Traboulsee","year":"2016","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"9","key":"10.1016\/j.msard.2026.107247_bib0239","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/jne.12157","article-title":"Novel aspects of glucocorticoid actions","volume":"26","author":"Uchoa","year":"2014","journal-title":"J. Neuroendocrinol."},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0240","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/ane.12667","article-title":"Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish multiple sclerosis association and the swedish neuroradiological society","volume":"135","author":"V\u00e5gberg","year":"2017","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2026.107247_bib0241","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104893","article-title":"Serum neurofilaments are a reliable biomarker to early detect PML in Multiple sclerosis patients","volume":"77","author":"Valentino","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"8","key":"10.1016\/j.msard.2026.107247_bib0242","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1007\/s00415-023-11676-4","article-title":"A multimodal marker for cognitive functioning in multiple sclerosis: the role of NfL, GFAP and conventional MRI in predicting cognitive functioning in a prospective clinical cohort","volume":"270","author":"van Dam","year":"2023","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0243","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000422","article-title":"Neurofilament light chain predicts disease activity in relapsing-remitting MS","volume":"5","author":"Varhaug","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2026.107247_bib0244","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.msard.2019.02.001","article-title":"Kappa free light chains could predict early disease course in multiple sclerosis","volume":"30","author":"Vecchio","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2026.107247_bib0245","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1007\/s00415-021-10945-4","article-title":"Cerebrospinal fluid biomarkers and cognitive functions at multiple sclerosis diagnosis","volume":"269","author":"Virgilio","year":"2022","journal-title":"J. Neurol."},{"issue":"14","key":"10.1016\/j.msard.2026.107247_bib0246","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler."},{"issue":"13","key":"10.1016\/j.msard.2026.107247_bib0247","doi-asserted-by":"crossref","first-page":"e1299","DOI":"10.1212\/WNL.0000000000008160","article-title":"Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD","volume":"93","author":"Watanabe","year":"2019","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.msard.2026.107247_bib0248","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrneurol.2015.157","article-title":"Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis\u2013establishing disease prognosis and monitoring patients","volume":"11","author":"Wattjes","year":"2015","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0249","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pathophys.2010.04.005","article-title":"The rs2030324 SNP of brain-derived neurotrophic factor (BDNF) is associated with visual cognitive processing in multiple sclerosis","volume":"18","author":"Weinstock-Guttman","year":"2011","journal-title":"Pathophysiology"},{"issue":"4\u20135","key":"10.1016\/j.msard.2026.107247_bib0250","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/13524585231155639","article-title":"Cerebrospinal fluid-related tissue damage in multiple sclerosis patients with iron rim lesions","volume":"29","author":"Wittayer","year":"2023","journal-title":"Mult. Scler."},{"issue":"1111","key":"10.1016\/j.msard.2026.107247_bib0251","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/postgradmedj-2017-135397","article-title":"Association between circulating leptin levels and multiple sclerosis: a systematic review and meta-analysis","volume":"94","author":"Xie","year":"2018","journal-title":"Postgrad. Med. J."},{"issue":"7","key":"10.1016\/j.msard.2026.107247_bib0252","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/jsxmed\/qdaf102","article-title":"Sexual function in people with multiple sclerosis: a systematic review and meta-analysis","volume":"22","author":"Yazdan Panah","year":"2025","journal-title":"J. Sex Med."},{"key":"10.1016\/j.msard.2026.107247_bib0253","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/neurosci7020034","article-title":"Slowly expanding lesions in Multiple sclerosis: a systematic review and meta-analysis","volume":"7","author":"Yazdan Panah","year":"2026","journal-title":"NeuroSci"},{"key":"10.1016\/j.msard.2026.107247_bib0254","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.3390\/ijms26073258","article-title":"Profiling blood-based neural biomarkers and cytokines in experimental autoimmune encephalomyelitis model of multiple sclerosis using single-molecule array technology","volume":"26","author":"Zahoor","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.msard.2026.107247_bib0255","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/ajmg.b.30332","article-title":"Brain derived neurotrophic factor (BDNF) gene variants and Alzheimer's disease, affective disorders, posttraumatic stress disorder, schizophrenia, and substance dependence","volume":"141b","author":"Zhang","year":"2006","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"issue":"1","key":"10.1016\/j.msard.2026.107247_bib0256","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-020-00303-7","article-title":"Chitinase-3 like-protein-1 function and its role in diseases","volume":"5","author":"Zhao","year":"2020","journal-title":"Signal. Transduct. Target Ther."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482600283X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482600283X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T03:45:39Z","timestamp":1780976739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482600283X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":256,"alternative-id":["S221103482600283X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107247","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fluid biomarkers in multiple sclerosis: Indicators of disease activity, progression, and treatment response","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107247","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107247"}}